Compare Gilead Sciences, Inc. (GILD) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Matson Inc — how do they compare? Gilead Sciences, Inc. trades at $133.43 (market cap $163.51B), while Matson Inc trades at $227.59 (market cap $6.32B). The key difference: Gilead Sciences, Inc. is far larger — about 25.9× Matson Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | MATX | |
|---|---|---|
Market Cap | $163.51B | $6.32B |
Sector | Health | Technology |
52-Week High | $155.80 | $210.95 |
52-Week Low | $108.22 | $88.05 |
Enterprise Value | $178.05B | $6.92B |
Dividend Yield | 2.49% | 0.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Matson (MATX) trades at $223.32, up 5.86% today, showing strong momentum. The stock is technically bullish with moving averages aligned positively, though oscillators signal some near-term caution. Fundamentally, the company maintains solid profitability with a 12.92% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights preliminary Q2 results expecting higher operating income and a dividend increase to $0.38 per share.
The outlook for MATX is positive, supported by earnings beats, dividend growth, and strategic fleet renewal. Key opportunities include its niche Pacific shipping routes and e-commerce demand. Risks involve exposure to global trade volatility and potential margin pressure from operational costs. Analyst consensus is bullish with 64% buy ratings, but investors should monitor quarterly earnings execution amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
